<?xml version="1.0" encoding="UTF-8"?>
<p>Emerging evidence suggests that managing cytokine storm in critically ill COVID-19 patients by using steroid or IL-6R blocking antibodies may be beneficial [
 <xref rid="R30" ref-type="bibr">30</xref>, 
 <xref rid="R59" ref-type="bibr">59</xref>]. In the case of fulminant systemic infection, patients may develop sepsis, ARDS, and multi-organ failure, which are not unique to coronavirus. Treatment with effective antiviral therapy is being sought; however, treatment of the systemic response to this viral infection is likely to be equally or more important. Overzealous host response to infection has been well described and involves a complex interaction of cytokine storm, inflammation, endothelial dysfunction, and pathologic coagulation [
 <xref rid="R60" ref-type="bibr">60</xref>-
 <xref rid="R63" ref-type="bibr">63</xref>].
</p>
